Detalhe da pesquisa
1.
Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC.
Ann Pharmacother
; 56(4): 503-504, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34344199
2.
Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis.
Clin Lymphoma Myeloma Leuk
; 22(8): 566-568, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35367193